Gene editing biotech Editas Medicine has signed a three-year R&D collab deal with Milan-based San Raffaele Telethon Institute for Gene Therapy to develop…

In our EuroBiotech roundup this week, Motif Bio sets IPO terms, MSP plans a £60 million laboratory development, Prokarium bags cash for plague R&D and more.

AstraZeneca has dropped 6 drug programs from its pipeline--with almost all the early-stage candidates being axed from its MedImmune biologics arms--in what is…

Genmab and J&J bag a breakthrough designation, Merck dumps ALK, uniQure yo-yos on gene therapy data and more.

BioMarin Pharmaceutical gained almost $1 billion in market cap on strong positive data for its gene therapy to treat severe hemophilia A.

Specialty pharma InnoPharma was acquired by Pfizer a few years ago for up to $360 million. Now, the team behind that effort is at it again with another…

GlaxoSmithKline will pay up to £175 million ($230 million) to gain global, exclusive rights to a Phase I monoclonal antibody to treat severe asthma from…

Unlikely IPO candidate Kadmon made it out in a tough IPO market amid swirling criticisms of its rather infamous current and former management, namely the…